DURHAM, N.C., April 25, 2019 — Premier Research will moderate a panel on cell-based therapies on Tuesday, April 30, at the Clinical Operations in Oncology Trials West Coast meeting in Burlingame, Calif.
Colin Hayward, the company’s chief medical officer, will lead a discussion about how researchers are overcoming the challenges inherent in creating cell-based cancer treatments. Panelists will be Luke Gill, vice president for oncology at Premier Research; Kristi Miller, head of regulatory affairs at Regulatory Professionals Inc., a division of Premier Research; and Athanasios Tsiatis, senior director for oncology clinical development at personalized medicine pioneer Plexxikon Inc.
The 30-minute discussion will begin at 4 p.m. April 30. Topics will include:
- Potential new strategic pathways for development of new therapies
- Design of early and proof-of-concept studies
- Enrolling and engaging with patients in trials for cell-based drugs
- Operational implementation of novel therapies
About Premier Research
Premier Research, a mid-size clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.
As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.
Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.